Published in BJU Int on January 16, 2007
Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev (2009) 1.03
Deregulation of FoxO3a accelerates prostate cancer progression in TRAMP mice. Prostate (2013) 0.94
Precursor lesions to prostatic adenocarcinoma. Virchows Arch (2008) 0.92
Beyond diagnosis: evolving prostate biopsy in the era of focal therapy. Prostate Cancer (2010) 0.89
Risks of testosterone replacement therapy in men. Indian J Urol (2014) 0.87
Challenges and potential solutions to meeting accrual goals in a Phase II chemoprevention trial for prostate cancer. Contemp Clin Trials (2011) 0.86
Heterogeneous clinicopathological features of intraductal carcinoma of the prostate: a comparison between "precursor-like" and "regular type" lesions. Int J Clin Exp Pathol (2014) 0.82
High-grade prostatic intraepithelial neoplasia. Korean J Urol (2012) 0.82
Significance of atypical small acinar proliferation and extensive high-grade prostatic intraepithelial neoplasm in clinical practice. Cent European J Urol (2014) 0.79
Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol (2009) 0.78
Is repeat biopsy for isolated high-grade prostatic intraepithelial neoplasia necessary? Rev Urol (2007) 0.78
Risk of prostate cancer after detection of isolated high-grade prostatic intraepithelial neoplasia (HGPIN) on extended core needle biopsy: a UK hospital experience. BMC Urol (2009) 0.78
Molecular Targeted Therapies Using Botanicals for Prostate Cancer Chemoprevention. Transl Med (Sunnyvale) (2012) 0.75
Non-invasive urinary metabolomic profiling discriminates prostate cancer from benign prostatic hyperplasia. Metabolomics (2017) 0.75
Suppression of Akt1- β-catenin pathway in advanced prostate cancer promotes TGFβ1-mediated epithelial to mesenchymal transition and metastasis. Cancer Lett (2017) 0.75
Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med (2008) 18.60
The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature (2002) 18.30
Retracted Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog (2006) 10.08
The surgical learning curve for prostate cancer control after radical prostatectomy. J Natl Cancer Inst (2007) 6.12
Regulation of Raf-1 by direct feedback phosphorylation. Mol Cell (2005) 5.88
Androgen-independent prostate cancer is a heterogeneous group of diseases: lessons from a rapid autopsy program. Cancer Res (2004) 5.88
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol (2008) 5.27
alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA (2002) 5.07
Human Proteinpedia enables sharing of human protein data. Nat Biotechnol (2008) 4.21
Effects of pathologic stage on the learning curve for radical prostatectomy: evidence that recurrence in organ-confined cancer is largely related to inadequate surgical technique. Eur Urol (2008) 3.93
Prediction of erectile function following treatment for prostate cancer. JAMA (2011) 3.92
EZH2 oncogenic activity in castration-resistant prostate cancer cells is Polycomb-independent. Science (2012) 3.74
The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am J Surg Pathol (2013) 3.68
Renal mass biopsy--a renaissance? J Urol (2007) 3.12
ALK-1 expression in inflammatory myofibroblastic tumor of the urinary bladder. Am J Surg Pathol (2004) 3.08
The role of pathology review of transurethral bladder tumor resection specimens in the modern era. J Urol (2010) 3.05
Saturation technique does not improve cancer detection as an initial prostate biopsy strategy. J Urol (2006) 3.02
The relationship between prostate-specific antigen and prostate cancer risk: the Prostate Biopsy Collaborative Group. Clin Cancer Res (2010) 2.87
Androgen deprivation falls as orchiectomy rates rise after changes in reimbursement in the U.S. Medicare population. Cancer (2008) 2.85
Radical prostatectomy, external beam radiotherapy <72 Gy, external beam radiotherapy > or =72 Gy, permanent seed implantation, or combined seeds/external beam radiotherapy for stage T1-T2 prostate cancer. Int J Radiat Oncol Biol Phys (2004) 2.84
Tolterodine extended release with or without tamsulosin in men with lower urinary tract symptoms including overactive bladder symptoms: effects of prostate size. Eur Urol (2008) 2.84
Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J Urol (2008) 2.83
An antioxidant response phenotype shared between hereditary and sporadic type 2 papillary renal cell carcinoma. Cancer Cell (2011) 2.78
Dipstick pseudohematuria: unnecessary consultation and evaluation. J Urol (2009) 2.75
Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology (2011) 2.68
Laparoscopic radical nephrectomy: incorporating advantages of hand assisted and standard laparoscopy. J Urol (2003) 2.61
Interleukin-8 mediates resistance to antiangiogenic agent sunitinib in renal cell carcinoma. Cancer Res (2010) 2.61
The learning curve for surgical margins after open radical prostatectomy: implications for margin status as an oncological end point. J Urol (2010) 2.61
Adjuvant and salvage radiotherapy after prostatectomy: AUA/ASTRO Guideline. J Urol (2013) 2.59
International validation of a preoperative nomogram for prostate cancer recurrence after radical prostatectomy. J Clin Oncol (2002) 2.51
Role of magnetic resonance imaging before initial biopsy: comparison of magnetic resonance imaging-targeted and systematic biopsy for significant prostate cancer detection. BJU Int (2011) 2.41
Office based transrectal saturation biopsy improves prostate cancer detection compared to extended biopsy in the repeat biopsy population. J Urol (2011) 2.38
Surgical resection of renal cell carcinoma after targeted therapy. J Urol (2009) 2.29
Histone H2A.Z cooperates with RNAi and heterochromatin factors to suppress antisense RNAs. Nature (2009) 2.19
Primary cryoablation nadir prostate specific antigen and biochemical failure. J Urol (2009) 2.18
Robotic real-time near infrared targeted fluorescence imaging in a murine model of prostate cancer: a feasibility study. Urology (2013) 2.15
Bacillus Calmette-Guérin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol (2009) 2.13
Avoiding androgen deprivation therapy in men with high-risk prostate cancer: the role of radical prostatectomy as initial treatment. Urology (2011) 2.12
Primary full-gland prostate cryoablation in older men (> age of 75 years): results from 860 patients tracked with the COLD Registry. BJU Int (2011) 2.12
Prostate cancer detection with office based saturation biopsy in a repeat biopsy population. J Urol (2004) 2.12
Structural and thermodynamic properties of selective ion binding in a K+ channel. PLoS Biol (2007) 2.10
Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol (2009) 2.10
Acceptance and durability of surveillance as a management choice in men with screen-detected, low-risk prostate cancer: improved outcomes with stringent enrollment criteria. Urology (2011) 2.07
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate (2010) 2.05
The International Society of Urological Pathology (ISUP) grading system for renal cell carcinoma and other prognostic parameters. Am J Surg Pathol (2013) 2.05
Contemporary role of systematic prostate biopsies: indications, techniques, and implications for patient care. Eur Urol (2012) 2.05
Lack of pathologic down-staging with neoadjuvant chemotherapy for muscle-invasive urothelial carcinoma of the bladder: a contemporary series. Cancer (2009) 2.02
Monotherapy for stage T1-T2 prostate cancer: radical prostatectomy, external beam radiotherapy, or permanent seed implantation. Radiother Oncol (2004) 2.01
Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol (2008) 2.00
Protein phosphatase 2A positively regulates Ras signaling by dephosphorylating KSR1 and Raf-1 on critical 14-3-3 binding sites. Curr Biol (2003) 1.98
A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol (2003) 1.96
MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. J Clin Invest (2013) 1.89
Focal cryotherapy for localized prostate cancer: a report from the national Cryo On-Line Database (COLD) Registry. BJU Int (2011) 1.88
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol (2008) 1.87
Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol (2010) 1.87
Fusion of ALK to the Ran-binding protein 2 (RANBP2) gene in inflammatory myofibroblastic tumor. Genes Chromosomes Cancer (2003) 1.86
Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol (2012) 1.85
Adult cystic nephroma and mixed epithelial and stromal tumor of the kidney are the same disease entity: molecular and histologic evidence. Am J Surg Pathol (2009) 1.84
The ubiquitin ligase gp78 promotes sarcoma metastasis by targeting KAI1 for degradation. Nat Med (2007) 1.81
Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy. J Urol (2009) 1.81
Inadequacy of biopsy for diagnosis of upper tract urothelial carcinoma: implications for conservative management. Urology (2011) 1.78
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis. Urology (2006) 1.75
Low testosterone and risk of biochemical recurrence and poorly differentiated prostate cancer at radical prostatectomy. Urology (2008) 1.71
Analytical validation of the Oncotype DX prostate cancer assay - a clinical RT-PCR assay optimized for prostate needle biopsies. BMC Genomics (2013) 1.70
CK2 Is a component of the KSR1 scaffold complex that contributes to Raf kinase activation. Curr Biol (2006) 1.69
A susceptibility locus at chromosome 3p21 linked to familial nasopharyngeal carcinoma. Cancer Res (2004) 1.65
The effect of sunitinib on primary renal cell carcinoma and facilitation of subsequent surgery. J Urol (2012) 1.65
Prognostic impact of positive surgical margins in surgically treated prostate cancer: multi-institutional assessment of 5831 patients. Urology (2005) 1.63
Female sexual dysfunction: classification, pathophysiology, and management. Fertil Steril (2007) 1.62
Office based flexible cystoscopy may be less painful for men allowed to view the procedure. J Urol (2007) 1.62
Immune synapse formation requires ZAP-70 recruitment by ezrin and CD43 removal by moesin. J Cell Biol (2007) 1.61
Diverse roles of HP1 proteins in heterochromatin assembly and functions in fission yeast. Proc Natl Acad Sci U S A (2009) 1.60
microRNA-141 is involved in a nasopharyngeal carcinoma-related genes network. Carcinogenesis (2010) 1.59
Prospective evaluation of prostate cancer risk in candidates for inguinal hernia repair. J Am Coll Surg (2009) 1.59
Can saturation biopsy predict prostate cancer localization in radical prostatectomy specimens: a correlative study and implications for focal therapy. Urology (2010) 1.58
A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol (2007) 1.57
Salvage focal prostate cryoablation for locally recurrent prostate cancer after radiotherapy: initial results from the cryo on-line data registry. Prostate (2014) 1.56
Gleason 6 prostate tumors diagnosed in the PSA era do not demonstrate the capacity for metastatic spread at the time of radical prostatectomy. Urology (2013) 1.56
Clinical correlates of renal angiomyolipoma subtypes in 209 patients: classic, fat poor, tuberous sclerosis associated and epithelioid. J Urol (2008) 1.55
Risk of prostate cancer after diagnosis of atypical glands suspicious for carcinoma on saturation and traditional biopsies. J Urol (2008) 1.53
Expression of PTEN and mTOR in sacral chordoma and association with poor prognosis. Med Oncol (2014) 1.50
Cortisone dissociates the Shaker family K+ channels from their beta subunits. Nat Chem Biol (2008) 1.50
Determining the course of the dorsal nerve of the clitoris. Urology (2008) 1.50
Analysis of T1c prostate cancers treated at very low prostate-specific antigen levels. Eur Urol (2008) 1.49
Laparoscopic partial nephrectomy for cystic masses. J Urol (2005) 1.49
Modulation of voltage-dependent Shaker family potassium channels by an aldo-keto reductase. J Biol Chem (2006) 1.48
Epithelial-to-mesenchymal transition in renal neoplasms. Adv Anat Pathol (2014) 1.47
Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol (2008) 1.47
Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46
Prognostic value of initial prostate-specific antigen levels after salvage cryoablation for prostate cancer. BJU Int (2010) 1.46
Stress-induced phosphorylation and proteasomal degradation of mitofusin 2 facilitates mitochondrial fragmentation and apoptosis. Mol Cell (2012) 1.46
Prostate cancer detection after a negative prostate biopsy: lessons learnt in the Cleveland Clinic experience. Int J Urol (2011) 1.46
Crystal structure of a bacterial homologue of the kidney urea transporter. Nature (2009) 1.46